Skip to main content
Home
  • Clinical Outcome Assessments
    Clinical Outcome Assessments

    What are Clinical Outcome Assessments (COAs)? What do they measure?

    Learn more about COAs
    Collaborating with questionnaire authors.
    The most trusted distributor of COAs

    700+ exclusive COA distributions on behalf of their copyright owners

    Author discussing assessment development.
    PROQOLID™: the largest COA database

    7,000+ COAs described in details and accessible in this unique database

  • Services
    Services

    Mapi Research Trust provides turnkey solutions for your Clinical Outcome Assessments (COAs) strategies - including COA databases, targeted literature reviews, licensing.

    Read More
    COA Databases Patient-Centered Endpoint Intelligence COA Licensing Translation and Linguistic Validation eCOA Licensing COA Repository
    Team reviewing questionnaire content.
    About ePROVIDE™

    Online access to all our services and COA databases

    Working on validation studies.
    What are eBooklets?

    Find out more about this step-by-step guidance for valid digitization of COAs

  • Author Collaboration
    Author Collaboration

    Our team is dedicated to assisting authors in the daily management of their questionnaires and all derivatives, including translations and electronic versions

    Read More
    COA distribution COA copyright and protection Promotion of COAs and developers Testimonials
    Reviewing translated assessments.
    Catalog of COAs distributed by Mapi Research Trust

    800+ exclusive distributions of COAs, accessible in ePROVIDE

  • Resources
    Resources

    ACCESS all our resources on COAs and eCOA: webinars, publications, blogs. SUBSCRIBE to receive email updates.

    Read More
    Blog Publications Useful links Webinar recordings Whitepapers
    Whitepaper-Digitizing-COAs.jpg
    New whitepaper

    Digitizing COAs: A streamlined approach to approval

    Developing new PRO instruments.
    New whitepaper

    COAs and copyright: How to mitigate risks of infringement and misuse in clinical research and practice

  • News & Events
    News & Events

    Stay informed with our latest news and check all our upcoming events. SUBSCRIBE to get email updates.

    Read More
    Scientific meeting about COAs.
    News
    Meeting with instrument developers.
    Conferences
    Discussion about PRO measures.
    Webinars
  • About us
    About us

    Mapi Research Trust is a non-profit organization dedicated to improving patients’ quality of life by facilitating access to Clinical Outcome Assessments(COAs).

    Read More
    Collaborative research session.
    Team

    A global team of multi-disciplinary experts

    Team analyzing PRO data.
    Experience

    Collecting & Processing Patient Centered Outcomes information for more than two decades

  • Contact
  1. Home
  2. News & Events
  3. News
  4. A reflection paper by EURORDIS and its Members

A reflection paper by EURORDIS and its Members

To celebrate the Rare Disease Day on Feb 28, 2017, we are pleased to share with our readers the Reflection Paper just published by EURORDIS this month.
http://www.eurordis.org/sites/default/files/reflexion-paper.pdf
This paper is a contribution of the community of rare disease patient advocates. It is a work in-progress by EURORDIS and its members, offering a synthesis of their analysis, reflections and perspectives on the issue of access to orphan medicines.
EURORDIS does not pretend to propose “the solution”, “the new model” or “the new deal”. This paper expresses a set of possibilities, not a position.
In his introduction, Yann le Cam, CEO EURORDIS-Rare Diseases Europe, expresses strong beliefs:
“We are strong about only one thing: when it comes to patients’ access, we do not take “no” for an answer. We cannot passively curb under the weaknesses of the current model. We stand up and speak for patient first. We, rare diseases patients, are not the problem: we are part of the solution.
Our beliefs are that viable new models or strategies can only be:

  • addressed if elevated to a more political level within each stakeholder constituency;
  • developed through a collective conversation involving all stakeholders, so as to be negotiated and co-constructed in a socially responsible manner;
  • shaped into a comprehensive framework with a global outlook in addition to addressing each technical element, each possibility.

This paper is not the “One-Text Paper” for the proposed cooperative process to reach mutually acceptable solutions that respect all stakeholders. If accepted and trusted by the participants to this multi-stakeholder symposium, the One-Text will be elaborated by a multi-stakeholder “group of drafters”, mostly composed of members of the Programme Committee, potentially starting from day one after the EURORDIS symposium, (Feb 22-23, 2017) and will be progressively developed in an iterative process of broad consultations until the next symposium in February 2018.
For more details about EURORDIS, please go to http://www.eurordis.org/

In this section
In this section
  • News
  • Events
    • Conferences
    • Webinars
Site Branding
    ICON plc
  • Contact
  • About Us
For Clients
  • Services
  • Resources
  • ePROVIDE™
News & Events
  • News
  • Conferences
  • Webinars
Socials
  • Linkedin

Legal Footer

  • © 2025 Mapi Research Trust
  • Disclaimer
  • Privacy
  • Site Cookies
How can we help?
  • All
Popular search terms:
  • COVID-19
  • Site & Patient Recruitment
  • Oncology
  • Medical Device
  • Real World Evidence
  • Decentralised & hybrid clinical trials
  • Digital Disruption